Details of the Drug

General Information of Drug (ID: DM28AZV)

Drug Name
Relatlimab
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [1]
Haematological malignancy 2B33.Y Phase 2/3 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Recurrent glioblastoma 2A00.00 Phase 1 [2]
Affected Organisms
Humans and other mammals
Cross-matching ID
UNII
AF75XOF6W3
DrugBank ID
DB14851
TTD ID
D0A3WJ
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lymphocyte activation gene 3 protein (LAG3) TTNVXAW LAG3_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761234
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)